Holen Sie sich die Stockscreener-App
22.74
6.23%
-1.51
Handel nachbörslich:
22.65
-0.09
-0.40%
Schlusskurs vom Vortag:
$24.25
Offen:
$23.12
24-Stunden-Volumen:
3.24M
Relative Volume:
1.22
Marktkapitalisierung:
$2.30B
Einnahmen:
$352.57M
Nettoeinkommen (Verlust:
$-143.01M
KGV:
-12.56
EPS:
-1.81
Netto-Cashflow:
$-153.40M
1W Leistung:
-13.96%
1M Leistung:
-11.69%
6M Leistung:
+12.35%
1J Leistung:
-6.65%
1-Tages-Spanne:
$22.58
$23.95
1-Wochen-Bereich:
$22.58
$26.40
52-Wochen-Spanne:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Firmenname
Beam Therapeutics Inc
Sektor
Branche
Telefon
857-327-8775
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie BEAM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
22.74 | 2.45B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Eingeleitet | Jefferies | Buy |
| 2025-03-28 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-10 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-08 | Herabstufung | Jefferies | Buy → Hold |
| 2023-10-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Eingeleitet | Citigroup | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2022-01-05 | Eingeleitet | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-24 | Fortgesetzt | Stifel | Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Redburn | Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-08-05 | Eingeleitet | William Blair | Outperform |
| 2020-03-02 | Eingeleitet | Barclays | Overweight |
| 2020-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2020-03-02 | Eingeleitet | Jefferies | Buy |
| 2020-03-02 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Beam Therapeutics Inc Aktie (BEAM) Neueste Nachrichten
Beam Therapeutics (BEAM): Losses Worsen as Profitability Remains Elusive Despite Rapid Revenue Growth Forecasts - Yahoo Finance
FMR LLC Reduces Stake in Beam Therapeutics Inc: A Strategic Move in the Biotech Sector - GuruFocus
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates - sharewise.com
Beam (BEAM) Advances Clinical Programs in Genetic Disease Base E - GuruFocus
Beam Therapeutics Q3 2025 Earnings: EPS Misses at -$1.10, Revenue Falls Short at $9.7 Million - GuruFocus
Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q3 Revenue $9.7M, vs. FactSet Est of $11.3M - MarketScreener
Beam Therapeutics Q3 net loss wider than expected on higher R&D expenses - MarketScreener
Visualizing Beam Therapeutics Inc. stock with heatmapsBuy Signal & Free Daily Entry Point Trade Alerts - newser.com
Beam Therapeutics Inc. SEC 10-Q Report - TradingView
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - The Manila Times
Oculis (NASDAQ: OCS) and EURETINA honor Prithvi Ramtohul, 2025 Ramin Tadayoni Awardee - Stock Titan
Analyzing drawdowns of Beam Therapeutics Inc. with statistical tools2025 Risk Factors & Intraday High Probability Alerts - newser.com
How Beam Therapeutics Inc. stock compares to market leadersWeekly Gains Report & Risk Controlled Stock Pick Alerts - newser.com
Beam Therapeutics Stock Faces Pivotal Week with Key Catalysts Ahead - AD HOC NEWS
ARK Investment Acquires Significant Stake in Beam Therapeutics ( - GuruFocus
Beam to present updated data on sickle cell gene therapy at ASH meeting - Investing.com
ASH 2025: Beam Therapeutics (NASDAQ: BEAM) to share updated BEAM-101 sickle cell data - Stock Titan
Why retail investors favor Beam Therapeutics Inc. stockTrade Performance Summary & Long-Term Capital Growth Ideas - newser.com
How buybacks impact Beam Therapeutics Inc. stock value2025 Trading Recap & AI Enhanced Trading Signals - newser.com
Historical volatility pattern of Beam Therapeutics Inc. visualizedStop Loss & Proven Capital Preservation Tips - newser.com
Institutional scanner results for Beam Therapeutics Inc.Market Rally & Fast Exit Strategy with Risk Control - newser.com
AMG National Trust Bank Buys Shares of 17,007 Beam Therapeutics Inc. $BEAM - MarketBeat
What is the fair value of Beam Therapeutics Inc. stock nowWeekly Trend Summary & Community Consensus Stock Picks - newser.com
Visual analytics tools that track Beam Therapeutics Inc. performanceMarket Activity Recap & Risk Controlled Stock Pick Alerts - newser.com
Why Beam Therapeutics Inc. stock is favored by pension fundsJuly 2025 Sentiment & Fast Momentum Entry Tips - newser.com
What analyst consensus says on Beam Therapeutics Inc. stock2025 Top Gainers & Daily Volume Surge Signals - newser.com
Real time social sentiment graph for Beam Therapeutics Inc.2025 Market Overview & Expert Curated Trade Ideas - newser.com
How to monitor Beam Therapeutics Inc. with trend dashboardsStop Loss & High Accuracy Trade Signal Alerts - newser.com
Published on: 2025-11-02 01:58:11 - newser.com
Will Beam Therapeutics Inc. stock deliver long term returnsPortfolio Profit Report & Weekly Top Performers Watchlists - newser.com
Should you wait for a breakout in Beam Therapeutics Inc.Sell Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Beam Therapeutics Inc. stock outperform Nasdaq indexInsider Buying & Stepwise Trade Signal Guides - newser.com
What hedge fund activity signals for Beam Therapeutics Inc. stockJuly 2025 Snapshot & Reliable Entry Point Trade Alerts - newser.com
Published on: 2025-10-31 03:50:40 - newser.com
ETFs Investing in Beam Therapeutics Inc. Stocks - TradingView
Finanzdaten der Beam Therapeutics Inc-Aktie (BEAM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):